The effect of prophylactic immune therapy in the III trimester on indicators of immune status in pregnant women with HCV infection
DOI:
https://doi.org/10.15574/PP.2025.1(101).3136Keywords:
HCV infection, course of pregnancy, functional state, the immune system, interferon, preventive immunotherapyAbstract
Аim - to study the effect of prophylactic immune therapy in the III trimester on indicators of immune status in pregnant women with hepatitis C virus (HCV) infection for the prevention of vertical transmission of hepatitis C virus from mother to child.
Materials and methods. A prospective clinical and statistical analysis of the immune status at 28 and 36 weeks of pregnancy was conducted in 74 women with HCV infection, the Group I - 40 pregnant women who received recombinant interferon, the Group II - 34 pregnant women who did not receive it. The control group (CG) consisted of 30 healthy pregnant women. The immunological examination was carried out during 28-36 weeks of pregnancy and included: determination of the absolute and relative number of lymphocyte subpopulations CD3+ (T-lymphocytes), CD4+ (helper-inducers), CD8+ (suppressors), immunoregulatory index (IRI) - ratio of CD4+/CD8+, CD19+ (B-lymphocytes); determination of IgG, IgM, IgA levels; IFN-α content. Statistical processing of research results was carried out using standard programs "Microsoft Excel 5.0" and "Statistica 8.0"
Results. Indicators of the relative and absolute content of CD8+-lymphocytes at 36 weeks of pregnancy in women of the Group I were significantly lower than the corresponding indicators in the Group II and did not differ from similar indicators of the CG. After the first course of prophylactic interferon therapy in the Group I, the average level of IFN-α differed from the initial level and from the similar indicator of the CG. In the Group II, the indicators of IFN-α at 36 weeks of gestation remained at a low level and were significantly lower when compared with similar indicators the CG. The difference between the average indicators of IRI at 36 weeks of pregnancy in the Groups I and II was significant.
Conclusions. Іmmune therapy to pregnant women with HCV infection contributed to a decrease in CD8+ lymphocytes and an increase in IRI, as well as an increase in the level of IFN-α.
The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of the institution mentioned in the paper. The informed consent of the patient was obtained for conducting the studies.
No conflict of interests was declared by the authors.
References
Abdel-Wahab N, Talathi S, Lopez-Olivo MA, Suarez-Almazor ME. (2018). Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analy-sis. Lupus. 27(4): 572-583. https://doi.org/10.1177/0961203317731532; PMid:28945149
Barritt AS, Jhaveri R. (2018). Treatment of Hepatitis C during Pregnancy-Weighing the Risks and Benefi tsin Contrast to HIV. Current HIV/AIDS reports. 15(2): 155-161. https://doi.org/10.1007/s11904-018-0386-z; PMid:29470782
Chappell CA, Hillier SL, Crowe D, Meyn LA, Bogen DL, Krans EE. (2018). Hepatitis C Virus Screening Among Children Exposed During Pregnancy. Pediatrics. 141(6): e20173273. https://doi.org/10.1542/peds.2017-3273; PMid:29720535 PMCid:PMC5984711
Chilaka VN, Konje JC. (2021). Viral Hepatitis in pregnancy. European journal of obstetrics, gynecology, and reproductive biology. 256: 287-296. https://doi.org/10.1016/j.ejogrb.2020.11.052; PMid:33259998
Compagnone A, Catenazzi P, Riccardi R, Zuppa AA. (2019). Mother-to-child transmission of hepatitis C virus. Minerva pediatrica. 71(2): 174-180. https://doi.org/10.23736/S0026-4946.18.04898-3; PMid:29968442
Dibba P, Cholankeril R, Li AA, Patel M et al. (2018). Hepatitis C in Pregnancy. Diseases (Basel, Switzerland). 6(2): 31. https://doi.org/10.3390/diseases6020031; PMid:29702563 PMCid:PMC6023348
Dobrowolska K, Brzdęk M, Rzymski P, Flisiak R, Pawłowska M, Janczura J et al. (2024, May). Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals. Expert Opin Pharmacother. 25(7): 833-852. Epub 2024 May 27. https://doi.org/10.1080/14656566.2024.2358139; PMid:38768013
El-Shabrawi M, Kamal NM, Mogahed EA, Elhusseini MA, Aljabri MF. (2019). Perinatal transmission of hepatitis C virus: an update. Archives of medical science: AMS. 16(6): 1360-1369. https://doi.org/10.5114/aoms.2019.83644; PMid:33224335 PMCid:PMC7667440
Epstein RL, Sabharwal V, Wachman EM, Saia KA, Vellozzi C et al. (2018). Perinatal Transmission of Hepatitis C Virus: Defi ning the Cascade of Care. The Journal of pediatrics. 203: 34-40.e1. https://doi.org/10.1016/j.jpeds.2018.07.006; PMid:30170857 PMCid:PMC6252153
Freriksen J, van Seyen M, Judd A, Gibb DM, Collins IJ, Greupink R et al. (2019). Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child. Alimentary pharmacology & therapeutics. 50(7): 738-750. https://doi.org/10.1111/apt.15476; PMid:31448450 PMCid:PMC6773363
García-Romero CS, Guzman C, Cervantes A, Cerbón M. (2019). Liver disease in pregnancy: Medical aspects and their implications for mother and child. Annals of hepatology. 18(4): 553-562. https://doi.org/10.1016/j.aohep.2019.04.009; PMid:31126882
Gowda C, Smith S, Crim L, Moyer K, Sánchez PJ, Honegger JR. (2021). Nucleic Acid Testing for Diagnosis of Perinatally Acquired Hepatitis C Virus Infection in Early Infancy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 73(9): e3340-e3346. https://doi.org/10.1093/cid/ciaa949; PMid:32640018 PMCid:PMC8563185
Huang QT, Hang LL, Zhong M, Gao YF, Luo ML, Yu YH. (2016). Maternal HCV infection is associated with intrauterine fetal growth disturbance: a meta-analysis of observational studies. Medicine. 95(35). https://doi.org/10.1097/MD.0000000000004777
Kushner T. (2023, Apr). Pregnancy and Hepatitis C Virus. Gastroenterol Hepatol (N Y). 19(4): 219-221. PMID: 37705843; PMCID: PMC10496346.
Mintser AP. (2018). Statisticheskie metodyi issledovaniya v klinicheskoy meditsine. Prakticheskaya meditsina. 3: 41-45.
Orekondy N, Cafardi J, Kushner T, Reau N. (2019, Nov). HCV in Women and Pregnancy. Hepatology. 70(5): 1836-1840. https://doi.org/10.1002/hep.30791; PMid:31135999
Public Health Center. (2018). Hepatitis C in Ukraine: epidemiological characteristics and severity assessment.
Ragusa R, Corsaro LS, Frazzetto E, Bertino E, Bellia MA, Bertino G. (2020). Hepatitis C Virus Infection in Children and Pregnant Women: An Updated Review of the Literature on Screening and Treatments. AJP reports. 10(1): e121-e127. https://doi.org/10.1055/s-0040-1709185; PMid:32257593 PMCid:PMC7108952
Rahim MN, Pirani T, Williamson C, Heneghan MA. (2021). Management of pregnancy in women with cirrhosis. United European gastroenterology journal. 9(1): 110-119. https://doi.org/10.1177/2050640620977034; PMid:33259738 PMCid:PMC8259114
Rana R, Dangal R, Singh Y, Gurung RB, Rai B, Sharma AK. (2021, Sep 11). Hepatitis C Virus Infection in Pregnancy and Children: Its Implications and Treatment Considerations with Directly Acting Antivirals: A Review. JNMA J Nepal Med Assoc. 59(241): 942-953. https://doi.org/10.31729/jnma.5501; PMid:35199739 PMCid:PMC9107891
Razavi H. (2020). Global epidemiology of viral hepatitis. Gastroenterology Clinics. 49(2): 179-189. https://doi.org/10.1016/j.gtc.2020.01.001; PMid:32389357
Roudot-Thoraval F. (2021). Epidemiology of hepatitis C virus infection. Clinics and research in hepatology and gastroenterology. 45(3): 101596. https://doi.org/10.1016/j.clinre.2020.101596; PMid:33610022
Zhang Y, Chen J, Liao T, Chen S, Yan J, Lin X. (2020). Maternal HBsAg carriers and pregnancy outcomes: a retrospective cohort analysis of 85,190 pregnancies. BMC Pregnancy and Childbirth. 20: 1-9. https://doi.org/10.1186/s12884-020-03257-4; PMid:33238912 PMCid:PMC7687687
World Health Organization. (2017). Global hepatitis report 2017: World Health Organization.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ukrainian Journal of Perinatology and Pediatrics
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal “Ukrainian Journal of Perinatology and Pediatrics” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license(СС BY-NC).
Authors transfer the copyright to the Journal “MODERN PEDIATRICS. UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
